W Fraser Symmans Selected Research

Residual Neoplasm

1/2022	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
1/2022	Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
11/2021	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
4/2017	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
7/2016	Adaptive Randomization of Neratinib in Early Breast Cancer.
7/2015	Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
5/2013	Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
2/2012	Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.
1/2008	PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
7/2007	Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

W Fraser Symmans Research Topics

Disease

118	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2002
87	Neoplasms (Cancer) 01/2022 - 08/2002
30	Pathologic Complete Response 12/2021 - 06/2005
17	Triple Negative Breast Neoplasms 12/2021 - 03/2008
14	Residual Neoplasm 01/2022 - 04/2004
9	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2002
4	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 01/2006
3	Inflammatory Breast Neoplasms 01/2021 - 02/2011
2	Neutropenia 01/2018 - 01/2013
2	Carcinoma (Carcinomatosis) 09/2015 - 04/2004
2	Carcinogenesis 11/2009 - 01/2009
1	Genomic Instability 11/2021
1	Neoplasm Micrometastasis 09/2020
1	Fatigue 01/2018
1	Febrile Neutropenia 01/2018

Drug/Important Bio-Agent (IBA)

27	Estrogen ReceptorsIBA 01/2020 - 02/2004
19	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 04/2004
16	Hormones (Hormone)IBA 01/2022 - 09/2003
16	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021 - 01/2003
15	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 04/2003
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2003
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
11	AnthracyclinesIBA 01/2021 - 04/2004
10	Fluorouracil (Carac)FDA LinkGeneric 11/2010 - 04/2003
9	RNA (Ribonucleic Acid)IBA 11/2021 - 10/2002
9	Trastuzumab (Herceptin)FDA Link 11/2021 - 01/2003
9	Messenger RNA (mRNA)IBA 02/2021 - 03/2004
8	Pharmaceutical PreparationsIBA 01/2022 - 07/2004
8	ParaffinIBA 02/2021 - 01/2003
8	Biological ProductsIBA 01/2021 - 08/2003
8	taxaneIBA 01/2021 - 04/2007
8	Tamoxifen FDA LinkGeneric 01/2021 - 04/2007
7	Carboplatin (JM8)FDA LinkGeneric 11/2021 - 07/2016
7	Estrogens (Estrogen)FDA Link 01/2021 - 07/2003
7	human ERBB2 proteinIBA 01/2021 - 03/2008
6	Formaldehyde (Formol)FDA Link 02/2021 - 02/2004
6	ErbB Receptors (EGF Receptor)IBA 01/2020 - 04/2004
6	DNA (Deoxyribonucleic Acid)IBA 04/2014 - 01/2008
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 03/2008
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 05/2014
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 01/2008
4	Docetaxel (Taxotere)FDA Link 01/2019 - 01/2003
3	veliparibIBA 11/2021 - 07/2016
3	pertuzumabIBA 11/2021 - 01/2018
3	Ado-Trastuzumab EmtansineIBA 11/2021 - 01/2018
3	Phenobarbital (Luminal)FDA Link 05/2019 - 08/2005
3	Taxoids (Taxanes)IBA 01/2013 - 12/2008
3	Complementary DNA (cDNA)IBA 01/2006 - 03/2003
3	Peptide Hydrolases (Proteases)FDA Link 03/2004 - 03/2003
2	Aromatase InhibitorsIBA 01/2022 - 01/2021
2	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 05/2019
2	TOR Serine-Threonine KinasesIBA 01/2020 - 05/2014
2	Dasatinib (BMS 354825)FDA Link 10/2014 - 05/2010
2	Phosphotransferases (Kinase)IBA 05/2014 - 11/2010
2	Imatinib Mesylate (Gleevec)FDA Link 05/2014 - 10/2004
2	Investigational DrugsIBA 05/2014 - 07/2012
2	Small Interfering RNA (siRNA)IBA 04/2014 - 11/2010
2	Monoclonal AntibodiesIBA 11/2009 - 04/2004
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2009 - 04/2004
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 04/2007 - 06/2005
2	Epirubicin (Ellence)FDA LinkGeneric 01/2007 - 06/2005
2	Hematoxylin (Haematoxylon)IBA 04/2004 - 08/2002
2	Eosine Yellowish-(YS) (Eosin)IBA 04/2004 - 08/2002
2	EnzymesIBA 04/2004 - 01/2003
2	Telomerase (Telomerase Reverse Transcriptase)IBA 03/2004 - 09/2003
2	Cell Adhesion MoleculesIBA 03/2004 - 09/2003
2	Transcription Factors (Transcription Factor)IBA 03/2004 - 09/2003
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	PhosphoproteinsIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 12/2021
1	olaparibIBA 12/2021
1	durvalumabIBA 12/2021
1	PlatinumIBA 11/2021
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 02/2021
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2021
1	Folate Receptor 1IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	mirvetuximab soravtansineIBA 01/2021
1	Estrogen Receptor alphaIBA 01/2021
1	Aurora Kinase AIBA 01/2021
1	Dihydrotestosterone (Androstanolone)IBA 01/2021
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2021
1	Progesterone FDA LinkGeneric 01/2021
1	MK 2206IBA 01/2020
1	pembrolizumabIBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2018
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2018
1	Cytochrome P-450 CYP2D6 InhibitorsIBA 01/2018
1	4-hydroxy-N-desmethyltamoxifenIBA 01/2018
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2018

Therapy/Procedure

49	Therapeutics 01/2022 - 01/2003
44	Neoadjuvant Therapy 01/2022 - 11/2002
42	Drug Therapy (Chemotherapy) 11/2021 - 08/2002
5	Aftercare (After-Treatment) 01/2018 - 11/2002
4	Adjuvant Chemotherapy 01/2020 - 05/2004
4	Segmental Mastectomy (Lumpectomy) 05/2012 - 09/2006
3	Combination Drug Therapy (Combination Chemotherapy) 01/2012 - 01/2010
2	Lymph Node Excision (Lymph Node Dissection) 09/2020 - 10/2013
2	Precision Medicine 04/2009 - 11/2006
1	Investigational Therapies (Experimental Therapy) 11/2021